Brokerage Firm Rating on ARIAD Pharmaceuticals (ARIA)

ARIAD Pharmaceuticals (ARIA) : Zacks Investment Research ranks ARIAD Pharmaceuticals (ARIA) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 2.2, which indicates as a Buy.

ARIAD Pharmaceuticals (ARIA) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $13 and the lowest price target forecast is $9. The average forecast of all the analysts is $10.6 and the expected standard deviation is $1.82.


For the current week, the company shares have a recommendation consensus of Buy. ARIAD Pharmaceuticals (NASDAQ:ARIA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.08 and $9.80 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.16, notching a gain of 1.91% for the day. The total traded volume was 5,137,451 . The stock had closed at $9.97 on the previous day.

In a related news, The Securities and Exchange Commission has divulged that Clackson Timothy P, officer (President, R&D, CSO) of Ariad Pharmaceuticals Inc, had unloaded 18,286 shares at an average price of $8.11 in a transaction dated on July 22, 2016. The total value of the transaction was worth $148,299.

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.